December 2024
Pragmatic Clinical Trials: Bridging the Gap Between Research and Real-World Practice
1. Pragmatic Clinical Trials, 2. Real-World Evidence, 3. Clinical Trial Design, 4. Effectiveness Research, 5. Healthcare Decision Making
Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset
Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024
Olema Secures $250 Million Funding for Pivotal Breast Cancer Trial Featuring Novartis’ Kisqali
Olema, Breast Cancer, Novartis, Kisqali, Pivotal Trial, Funding
Novartis Invests $1 Billion in PTC’s Huntington’s Disease Program
Novartis, PTC, Huntington’s disease, pharmaceutical investment, gene therapy
Sanofi Invests €1 Billion in Beijing to Enhance Insulin Production Capacity
Sanofi, insulin production, Beijing, investment, pharmaceutical industry
Merus’ Petosemtamab Demonstrates Promising Efficacy in Head and Neck Cancer, Enhancing Its ‘Best-in-Disease’ Profile
Petosemtamab, Head and Neck Cancer, Clinical Trials, Merus, ESMO Asia Congress 2024, Biclonics, EGFR and LGR5
FDA Rejects Govorestat for Classic Galactosemia, Citing Clinical Deficiencies
FDA rejection, govorestat, classic galactosemia, Applied Therapeutics, rare disease drug approval, clinical deficiencies
Novartis Invests $1 Billion in PTC Therapeutics’ Huntington’s Disease Program
Novartis, PTC Therapeutics, Huntington’s disease, Phase 2 drug, global license agreement, collaboration, upfront payment, milestone payments.
European Commission Revokes Marketing Authorization for Ocaliva, a Liver Disease Drug, Amid Regulatory Dispute
Ocaliva, European Commission, Marketing Authorization, Liver Disease, Primary Biliary Cholangitis (PBC), Advanz Pharma